Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Concerned about drug–drug interactions between DOACs and prostate cancer therapies?
New study of 2297 patients from Ontario and Alberta:
- No elevated risk for thrombosis with DOACs plus enzalutamide/ apalutamide
- No elevated risk for bleeding with DOAC plus abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont, Cynthia Wu, Pietro Ravani, Dominick Bossé, Robert Talarico, Marc Carrier, Manish M. Sood
Read the Full Article on Cancer
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 16, 2026, 15:24Hiteshi K.C. Chauhan: Oral Anticoagulant Reversal in Major Bleeding and Urgent Surgery
-
Jun 16, 2026, 14:50Abdulrahman Nasiri: Honored to Share our Research Contributions at the EHA 2026
-
Jun 16, 2026, 14:49An Overview of Bernard–Soulier Syndrome – ICHCC
-
Jun 16, 2026, 14:47David Walcott: Blood Supply as Essential Healthcare Infrastructure
-
Jun 16, 2026, 14:36Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care
-
Jun 16, 2026, 14:30Jeffrey Kallberg: Education and Advocacy at the Texas Bleeding Disorders Conference
-
Jun 16, 2026, 14:23Alfadil Haroon: Bleeding Outcomes in Congenital Versus Acquired FXIII Deficiency
-
Jun 16, 2026, 14:20Matthew James: Anticoagulation Errors – 5 Prescribing Red Flags That Lead to Bleeding
-
Jun 16, 2026, 14:13Miguel Crato: Pleased to Share the Farewell Speech Closing My Chapter as President of the EHC